What is Wedbush's Forecast for Geron Q1 Earnings?
Wedbush has released its Q1 2026 earnings estimates for Geron Corporation (NASDAQ: GERN), projecting an EPS of ($0.02). The consensus for the full year is ($0.25) per share. Geron reported a revenue of $49.04 million for the last quarter, exceeding expectations. The stock has received mixed ratings from analysts, with a consensus rating of "Moderate Buy" and a target price of $4.61. Geron focuses on therapeutics for hematologic malignancies, with its key product, imetelstat, in Phase 3 trials.
- Geron Corporation: FDA Approval Fuels Stock Price Surge
Geron Corporation (NASDAQ:GERN - Free Report) - Wedbush issued their Q1 2026 earnings per share (EPS) estimates for Geron in a research note issued to investors on Wednesday, August 6th. Wedbush analyst R. Driscoll expects that the biopharmaceutical company will earn ($0.02) per share for the quarter. The consensus estimate for Geron's current full-year earnings is ($0.25) per share. Wedbush also issued estimates for Geron's Q2 2026 earnings at $0.00 EPS, Q3 2026 earnings at $0.02 EPS, Q4 2026 earnings at $0.04 EPS, FY2026 earnings at $0.04 EPS and FY2027 earnings at $0.37 EPS.
Geron (NASDAQ:GERN - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.03) by $0.01. The business had revenue of $49.04 million during the quarter, compared to analysts' expectations of $47.30 million. Geron had a negative return on equity of 30.79% and a negative net margin of 53.52%. The business's quarterly revenue was up 5455.6% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.10) earnings per share.
- Geron Stock Doubles After Imetelstat Receives FDA Panel Approval
GERN has been the subject of several other research reports. The Goldman Sachs Group initiated coverage on Geron in a research report on Thursday, July 10th. They set a "sell" rating and a $1.00 target price for the company. Scotiabank cut Geron from a "sector outperform" rating to a "sector perform" rating and cut their target price for the stock from $4.00 to $1.50 in a research report on Thursday, May 8th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Geron has a consensus rating of "Moderate Buy" and a consensus price target of $4.61.
View Our Latest Stock Report on GERN
Geron Stock Performance
GERN traded down $0.02 during midday trading on Friday, reaching $1.29. The company had a trading volume of 2,104,608 shares, compared to its average volume of 12,713,486. The company has a quick ratio of 6.97, a current ratio of 7.87 and a debt-to-equity ratio of 0.44. The business has a 50-day moving average of $1.39 and a two-hundred day moving average of $1.68. The company has a market cap of $818.44 million, a P/E ratio of -9.88 and a beta of 0.73. Geron has a 1 year low of $1.09 and a 1 year high of $4.84.
Institutional Investors Weigh In On Geron
Institutional investors have recently modified their holdings of the stock. Integrated Wealth Concepts LLC bought a new stake in shares of Geron in the 4th quarter valued at approximately $36,000. GF Fund Management CO. LTD. purchased a new stake in Geron in the fourth quarter worth $45,000. 111 Capital bought a new stake in shares of Geron during the fourth quarter worth $52,000. Fifth Lane Capital LP bought a new stake in shares of Geron during the fourth quarter worth $53,000. Finally, Harvest Investment Services LLC bought a new stake in shares of Geron during the fourth quarter worth $61,000. 73.71% of the stock is owned by institutional investors.
About Geron
(Get Free Report)Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.
See Also
- Five stocks we like better than Geron
- What is the MACD Indicator and How to Use it in Your Trading
- Why Axon's 16% Surge Signals a New Era in Public Safety Tech
- High Dividend REITs: Are They an Ideal Way to Diversify?
- DraftKings Posts Record Quarter, Eyes Profitability
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Amazon Takes an Equity Stake in IonQ—Any Upside Potential?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Geron Right Now?
Before you consider Geron, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Geron wasn't on the list.
While Geron currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
